| Literature DB >> 30712048 |
Sara Ibrahim Alshahwan1, Ghada Alsowailmi, Afnan Alsahli, Amal Alotaibi, Murtadha Alshaikh, Mohammed Almajed, Aamir Omair, Hind Almodaimegh.
Abstract
BACKGROUND: Pneumonia, the commonest lower respiratory tract infection, can result in respiratory and non-respiratory complications. Few studies have reported on the prevalence of many complications.Entities:
Mesh:
Year: 2019 PMID: 30712048 PMCID: PMC6464674 DOI: 10.5144/0256-4947.2019.29
Source DB: PubMed Journal: Ann Saudi Med ISSN: 0256-4947 Impact factor: 1.526
Demographic and clinical characteristics of the patients (N=800).
| Characteristics | n (%) |
|---|---|
|
| |
| 17–45 | 128 (16) |
| 46–65 | 212 (27) |
| >65 | 460 (58) |
| Male | 373 (47) |
| Female | 427 (53) |
| Saudi | 794 (99) |
| Non-Saudi | 6 (1) |
| Diabetes mellitus | 530 (66) |
| Chronic kidney disease | 175 (22) |
| Cystic fibrosis | 1 (0.1) |
| Chronic obstructive pulmonary disease | 154 (19) |
| Asthma | 236 (30) |
| Lung cancer | 30 (4) |
| Smoker | 101 (13) |
| Immunosuppressant therapy | 82 (10) |
The prevalence of complications in patients with pneumonia (N=800).
| Complication | n (%) |
|---|---|
|
| |
| Respiratory complications | |
| Sepsis | 183 (23) |
| Cardiac complications | |
| Acute respiratory distress | 118 (15) |
| Unilateral | 120 (15) |
| Bilateral | 110 (14) |
| Septic shock | 94 (12) |
| Heart failure | 75 (9) |
| Arrhythmias | 52 (6.5) |
| Bronchiectasis | 22 (3) |
| Pleurisy | 10 (1.3) |
| Acute coronary syndrome | 8 (1) |
| Empyema | 8 (1) |
| Neurological complications | |
| Encephalitis | 5 (0.6) |
| Encephalitis | 5 (0.6) |
| Pulmonary abscess | 2 (0.3) |
| Endocarditis | 2 (0.3) |
| Cholestatic jaundice | 2 (0.3) |
| Pericarditis | 1 (0.1) |
| Myocarditis | 1 (0.1) |
Association between age groups and specific complications.
| Complication | Age groups | |||
|---|---|---|---|---|
| 17 to 45 years (n=128) | 46 to 65 years (n=212) | > 65 years (n=460) | ||
|
| ||||
| Acute respiratory distress | 13 (10%) | 29 (14%) | 76 (17%) | .18 |
| Unilateral pleural effusion | 20 (16%) | 20 (9%) | 80 (17%) | .03 |
| Bilateral pleural effusion | 14 (11%) | 20 (9%) | 76 (17%) | .03 |
| Heart failure | 3 (2%) | 19 (9%) | 53 (12%) | .007 |
| Sepsis | 17 (13%) | 37 (18%) | 129 (28%) | <.001 |
| Septic shock | 10 (8%) | 21 (10%) | 63 (14%) | .12 |
Association between type of pneumonia and specific complications.
| Complication | Type of pneumonia | ||
|---|---|---|---|
| CAP (n=640) | HAP (n=160) | ||
|
| |||
| Acute respiratory distress disease | 87 (14%) | 31 (19%) | .07 |
| Unilateral pleural effusion | 88 (14%) | 32 (20%) | .048 |
| Bilateral pleural effusion | 87 (14%) | 23 (14%) | .80 |
| Heart failure | 52 (8%) | 23 (14%) | .02 |
| Sepsis | 123 (19%) | 60 (38%) | <.001 |
| Septic shock | 64 (10%) | 30 (19%) | .002 |
| Encephalitis | 1 (0.2%) | 4 (3%) | .001 |
CAP: Community acquired pneumonia, HAP: Hospital acquired pneumonia
Figure 1Presence of complications by age groups.
Figure 2Frequency of comorbidities among patients with complications (n=427).
Figure 3Frequency of comorbidities among patients with (n=427) and without complications (n=373). Percentages are portion with complications for each number of comorbidities (two patients had 5 comorbidities) (0 vs 1: P=.9; 0 vs 2, P=.6; 0 vs 3, P=.002).
Multiple logistic regression of risk factors for presence of any complication.
| n | Wald | Sig. | Exp(B) | 95% CI for EXP(B) | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
|
| ||||||
| 17–45 | 128 | 10.35 | .006 | |||
| 46–65 | 212 | 0.05 | 0.82 | 1.06 | 0.64 | 1.76 |
| >65 | 460 | 5.24 | .02 | 1.73 | 1.08 | 2.78 |
| Male | 373 | 1.00 | ||||
| Female | 427 | 0.28 | 0.60 | 1.09 | 0.80 | 1.49 |
| Diabetes mellitus | 530 | 0.001 | 0.98 | 1.004 | 0.70 | 1.43 |
| Chronic kidney disease | 175 | 2.47 | 0.12 | 1.35 | 0.93 | 1.95 |
| Chronic obstructive pulmonary disease | 154 | 2.70 | 0.10 | 1.40 | 0.94 | 2.09 |
| Asthma | 236 | 0.91 | 0.34 | 1.17 | 0.85 | 1.63 |
| Smoker | 101 | 1.38 | 0.24 | 1.33 | 0.82 | 2.16 |
| Immunocompromised | 34 | 9.36 | .002 | 4.35 | 1.70 | 11.14 |
| Immunosuppressant therapy | 82 | 0.04 | 0.83 | 1.06 | 0.63 | 1.76 |
| Community acquired | 640 | 1.00 | ||||
| Hospital acquired | 160 | 20.20 | <.001 | 2.42 | 1.65 | 3.56 |
| Constant | 9.89 | <.001 | 0.51 | |||
Omnibus tests of model coefficients: Chi-square=62.892, df=11, P<.001; −2 log likelihood: 1042.496; Cox and Snell R Square: .076; Nagelkerke R square: .101